View Older Stories View More Recent Stories
-
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine
-
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine
-
Vivace Therapeutics Raises $35 Million in Series D Financing to Support Clinical Development of First-in-Class Cancer Drug Targeting the Hippo Pathway
-
Form SCHEDULE 13D/A Janux Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
-
Form SCHEDULE 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Be Biopharma Announces Appointment of Susan Abu-Absi, Ph.D. as Chief Operating Officer
-
Form SCHEDULE 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Weekly Roundup: 12 Finance Press Releases You Need to See
-
T-knife Therapeutics Welcomes Dr. Sophie Papa to its Board of Directors
-
Form SCHEDULE 13D Sionna Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Solid Biosciences (SLDB) Prices 35.74M Share Offering at $4.03/sh
-
Solid Biosciences Announces Pricing of Underwritten Offering
-
Form SCHEDULE 13G/A Verona Pharma plc Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Tenaya Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A NewAmsterdam Pharma Co Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Protara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A RECURSION PHARMACEUTICAL Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A MACROGENICS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A GLYCOMIMETICS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Longboard Pharmaceutical Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A EyePoint Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Evolent Health, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Ensysce Biosciences, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Day One Biopharmaceutica Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Adagio Medical Holdings, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Cytek Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A 4D Molecular Therapeutic Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A CYBIN INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A BioAge Labs, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A AN2 Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Monopar Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Zura Bio Ltd Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Dec 31
-
Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases
-
T-knife Therapeutics to Participate in Two Investor Conferences in MarchÂ
-
Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis
-
Be Biopharma Announces Publication of Manuscript in the Molecular Therapy Journal Demonstrating In Vivo Engraftment and Tracking of Ex-vivo-Generated Plasma Cells in Non-Human Primates
-
Form SCHEDULE 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Sortera Technologies' Board Names Kenneth Leet Chairman of the Board
-
Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company
-
GSK (GSK) to Acquire IDRx
-
GSK Enters Agreement to Acquire IDRx, Inc.
-
Verdiva Bio, a New Clinical-Stage Cardiometabolic Company, Launches with Over $410M in Series A Financing to Advance Next-Generation Therapies
-
Be Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
-
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

